Tighter blood pressure target may slash heart risks in hormone disorder
NCT ID NCT07673445
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial compares two blood pressure targets in people with primary aldosteronism, a hormonal condition that causes high blood pressure. One group aims for a systolic pressure below 120 mmHg (intensive), the other between 120 and 140 mmHg (standard). Over 6 to 10 years, researchers track heart attacks, strokes, and other cardiovascular events to see if tighter control offers greater protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
antihypertensive medications
What this could lead to
If intensive control works, it could establish a new, more effective blood pressure target to prevent heart attacks and strokes in people with primary aldosteronism.
What could go wrong
This is a large but early-stage comparison; intensive control may cause more side effects like dizziness or fainting, and the benefit over standard care may be small or absent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••